Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.84 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.84 |
| ▸ | KCNH3 | Q9ULD8 | 6/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | CA12 | O43570 | 1/20 | 0.65 |
| ▸ | CA1 | P00915 | 1/20 | 0.65 |
| ▸ | CA2 | P00918 | 1/20 | 0.65 |
| ▸ | CA5A | P35218 | 1/20 | 0.65 |
| ▸ | CA9 | Q16790 | 1/20 | 0.65 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.65 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.65 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | GBA1 | P04062 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3294674 | 0.92 | RECQL (1.00) | RECQLMCL1KCNH3TDP1GBA1 | |
| SCHEMBL3203902 | 0.91 | RECQL (0.69) | RECQLMCL1KCNH3MAPTKMT2A | |
| SCHEMBL17577161 | 0.90 | MEN1 (0.79) | RECQLMCL1KCNH3MAPTKMT2A | |
| SCHEMBL23321501 | 0.85 | MAPT (0.70) | RECQLMCL1KCNH3MAPTKMT2A | |
| SCHEMBL6235017 | 0.84 | NR1I2 (0.78) | RECQLMCL1KCNH3MAPTKMT2A | |
| SCHEMBL27393423 | 0.84 | RECQL (0.84) | RECQLMCL1KCNH3MAPTKMT2A | |
| SCHEMBL17563700 | 0.84 | MEN1 (0.69) | RECQLMCL1KCNH3MAPTKMT2A | |
| SCHEMBL15102355 | 0.83 | RECQL (0.82) | RECQLMCL1KCNH3TDP1GBA1 | |
| SCHEMBL17563710 | 0.83 | MEN1 (0.67) | RECQLMCL1KCNH3MAPTKMT2A | |
| SCHEMBL1923883 | 0.83 | MAPT (1.00) | RECQLMCL1KCNH3MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100189726-A1 | LPAAT-BETA INHIBITORS AND USES THEREOF | CELL THERAPEUTICS, INC. (US) | 2010-07-29 | — | — | US | claimed |
| US-20070072856-A1 | LPAAT-beta inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2007-03-29 | — | — | US | claimed |
| US-7064125-B2 | LPAAT-β inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2006-06-20 | — | — | US | claimed |
| US-20060035896-A1 | LPAAT-beta inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2006-02-16 | — | — | US | claimed |
| US-20040162288-A1 | LPAAT-beta inhibitors and uses thereof | CELL THERAPEUTICS, INC. | 2004-08-19 | — | — | US | claimed |
| WO-2002036578-A9 | TRIAZINE DERIVATIVES AS LPAAT-B INHIBITORS AND USES THEREOF | BONHAM LYNN (US) | 2004-04-22 | — | — | WO | claimed |
| US-20030100557-A1 | LPAAT-beta inhibitors and uses thereof | CELL THERAPEUTICS, INC. | 2003-05-29 | — | — | US | claimed |
| US-20020103195-A1 | LPAAT-B inhibitors and uses thereof | CELL THERAPEUTICS,INC. | 2002-08-01 | — | — | US | claimed |
| WO-2002036578-A2 | TRIAZINE DERIVATIVES AS LPAAT-B INHIBITORS AND USES THEREOF | BONHAM LYNN (US) | 2002-05-10 | — | — | WO | claimed |
| US-20100189726-A1 | LPAAT-BETA INHIBITORS AND USES THEREOF | CELL THERAPEUTICS, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-7683061-B2 | Triazine dimers for the treatment of autoimmune diseases | PROMETIC BIOSCIENCES INC. (CA) | 2010-03-23 | — | — | US | disclosed |
| US-7683061-B2 | Triazine dimers for the treatment of autoimmune diseases | PROMETIC BIOSCIENCES INC. (CA) | 2010-03-23 | — | — | US | disclosed |
| US-7608620-B2 | LPAAT-β inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2009-10-27 | — | — | US | disclosed |
| US-20070149528-A1 | Triazine dimers for the treatment of autoimmune diseases | PROMETIC PHARMA SMT LIMITED (GB) | 2007-06-28 | — | — | US | disclosed |
| US-20060035896-A1 | LPAAT-beta inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2006-02-16 | — | — | US | disclosed |
| US-20040162288-A1 | LPAAT-beta inhibitors and uses thereof | CELL THERAPEUTICS, INC. | 2004-08-19 | — | — | US | disclosed |
| WO-2002036578-A9 | TRIAZINE DERIVATIVES AS LPAAT-B INHIBITORS AND USES THEREOF | BONHAM LYNN (US) | 2004-04-22 | — | — | WO | disclosed |
| US-20030100557-A1 | LPAAT-beta inhibitors and uses thereof | CELL THERAPEUTICS, INC. | 2003-05-29 | — | — | US | disclosed |
| US-20020103195-A1 | LPAAT-B inhibitors and uses thereof | CELL THERAPEUTICS,INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2002036578-A2 | TRIAZINE DERIVATIVES AS LPAAT-B INHIBITORS AND USES THEREOF | BONHAM LYNN (US) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035896-A1 | LPAAT-beta inhibitors and uses thereof | LPCAT3, LPCAT1, PLAAT2 | RECQL 4128/4885MCL1 901/4885KCNH3 3747/4885 |
| US-20100189726-A1 | LPAAT-BETA INHIBITORS AND USES THEREOF | LPCAT3, LPCAT1, PLAAT2 | RECQL 4114/4885MCL1 1029/4885KCNH3 3421/4885 |
| US-20020103195-A1 | LPAAT-B inhibitors and uses thereof | LPCAT3, LPCAT1, PLAAT2 | RECQL 3609/4885MCL1 1043/4885KCNH3 3565/4885 |
| US-20070149528-A1 | Triazine dimers for the treatment of autoimmune diseases | SSB, TLR5, ICOS | RECQL 4175/4885MCL1 706/4885KCNH3 2097/4885 |
| US-20070072856-A1 | LPAAT-beta inhibitors and uses thereof | LPCAT3, LPCAT1, PLAAT2 | RECQL 4114/4885MCL1 1029/4885KCNH3 3421/4885 |
| US-20040162288-A1 | LPAAT-beta inhibitors and uses thereof | LPCAT3, LPCAT1, PLAAT2 | RECQL 3851/4885MCL1 1185/4885KCNH3 3428/4885 |
| US-20030100557-A1 | LPAAT-beta inhibitors and uses thereof | LPCAT3, LPCAT1, PLAAT2 | RECQL 3851/4885MCL1 1185/4885KCNH3 3428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.